The Food and Drug Administration today announced new efforts to spotlight situations where drugmakers may be pursuing “gaming tactics” to delay generic competition. “Today, we’re making public a list of companies that have potentially been blocking access to the samples of their branded products,” FDA Commissioner Scott Gottlieb, M.D., said in a statement. “We hope that this increased transparency will help reduce unnecessary hurdles to generic drug development and approval.” The information on the webpage includes, among other things, the brand drug company, the drug product and the number of inquiries FDA has received. “We’ll continue to look at more ways we can expand upon today’s action and call public attention to situations where the careful balance that Congress sought between product innovation and access may be being disrupted,” Gottlieb said.

Related News Articles

Headline
The House Energy and Commerce Committee today approved legislation to address surprise medical bills and Medicaid disproportionate share hospital cuts.
Headline
A federal judge yesterday struck down a Centers for Medicare…
Headline
The House Energy and Commerce Subcommittee on Health today held a hearing on seven bills aimed at improving transparency in the drug supply chain to lower…
Headline
The Centers for Medicare…
Headline
The largest U.S. pharmaceutical and biotech companies spend just 22 cents out of every dollar on research and development, according to an analysis released…
Blog
A recent Health Affairs blog post (April 19) on hospital price transparency argues that chargemaster data can be confusing to consumers. We agree, and have…